Does a higher NAD result mean better health?

The missing link

A biomarker can show that an intervention interacts with a biological pathway. To treat it as a substitute for a health outcome, researchers need evidence that changing it reliably predicts that outcome. NAD studies should therefore be read on two tracks: what changed in the sample, and what changed for the participant. Strong evidence on the first track does not automatically close the second.

A muscle study makes the distinction visible

Elhassan and colleagues gave 12 older men NR or placebo in a double-blind crossover study lasting 21 days per treatment. Muscle NAD-related metabolites changed, while mitochondrial bioenergetics did not. This is useful mechanistic evidence, precisely because the investigators measured more than a circulating marker. It also shows why an article should preserve a null physiological result alongside an interesting biochemical finding.

A cognitive pilot asks another question

A 2023 randomized pilot enrolled 20 adults with mild cognitive impairment for ten weeks. NR increased blood NAD, and the study collected cognition and other measures. Its small size and short duration limit conclusions about cognitive protection or disease progression. A successful increase in the targeted blood measure is not proof that a treatment prevents dementia, and the trial should not be marketed as if it answered that much larger question.

A result depends on its sample

Plasma, whole blood and an isolated cell population are different materials. A percentage change also depends on the starting value, collection timing and analytical method. It is unsafe to treat the largest reported percentage across unrelated studies as the best product. Without a common assay and comparable participants, even technically correct numbers can produce a misleading comparison. The specimen and method belong beside the headline.

What would establish usefulness

For a consumer test to guide a purchase, evidence should connect the measured result to a decision that improves outcomes. For example, investigators might test whether people selected by a particular baseline value benefit more, and whether changing treatment according to repeat testing helps. Those are additional research questions. A vendor showing that a test moves after its own supplement has established responsiveness, not necessarily clinical usefulness.

Avoid a moving target

A monitoring plan becomes hard to interpret if success is redefined whenever a new result arrives. Before looking at a follow-up report, decide which outcome was the reason for testing and which change would matter. Keep that outcome visible even when a secondary marker improves. Otherwise, any movement on a sufficiently broad panel can become a success story.

The same discipline applies to research headlines. A study that meets a biochemical objective may be a good study without establishing the benefit a seller wants to advertise. Reporting the actual objective protects both the science and the reader. It allows an interesting pathway result to remain interesting while preserving the need for trials that address function, symptoms or disease.

How to read your next claim

Ask for the actual outcome, comparator and population before interpreting words such as optimized or youthful. If the company cannot explain what a changed number means for a person, keep the claim at the biomarker level. A clinician can put symptoms and other findings into context; a supplement dashboard cannot provide that context by color coding a result. Our NAD-test guide examines those purchasing questions in more detail.